Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966590 | 0.91 | CA12 (0.49) | CA12CA9HSD11B1MEN1KMT2A | |
| SCHEMBL966298 | 0.90 | CA12 (0.50) | CA12CA9HSD11B1MEN1KMT2A | |
| SCHEMBL963555 | 0.87 | HSD11B1 (0.46) | CA12CA9HSD11B1MEN1KMT2A | |
| SCHEMBL962182 | 0.84 | L3MBTL1 (0.48) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL964483 | 0.80 | MEN1 (0.44) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL963199 | 0.78 | GAA (0.46) | MEN1KMT2ARAB9AMAPTLMNA | |
| SCHEMBL963233 | 0.78 | MEN1 (0.44) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL963552 | 0.77 | MEN1 (0.46) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4602434 | 0.76 | LMNA (0.50) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL964699 | 0.76 | GBA1 (0.50) | HSD11B1MEN1KMT2AMAPTPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | CA12 4707/4885CA9 3464/4885HSD11B1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.